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Introduction
Infection with SARS-CoV-2, the cause of coronavirus infectious disease–19 (COVID-19), has caused a pandemic after
first being reported in Wuhan, China in December 2019.1 An
over-representation of patients with cancer has been seen
in the COVID-19 cohort in the Chinese National Database
Repository.2 Patients with cancer have been reported to have
COVID-19-related case fatality rates of approximately 5–6%,1
and a 3 to 5-fold higher risk of severe COVID-19, compared to
the general population.2 Moreover, patients with hematological malignancies and COVID-19 have been reported to have
case fatality rates of up to 37%.3 Another study delineated
higher mortality in hospitalized patients with hematological
cancers who developed COVID-19 than in hospitalized healthcare providers with COVID-19.4
Severe and prolonged immunosuppression is a corollary
of treatment for acute lymphocytic leukemia (ALL), which
heightens the risk of complications associated with COVID-

19. Much remains to be known about incidence, management
and outcomes of COVID-19 in patients with cancer in general,
and leukemias in particular. We report on a case of a young
adult male with T-ALL, who was receiving chemotherapy and
developed COVID-19.

Case report
A 24-year-old male, presented in August 2019 with dyspnea
and loss of appetite during the previous 2 months. On examination, he was pale and had bilateral cervical and axillary
lymphadenopathy along with splenomegaly. The complete
blood count (CBC) showed hemoglobin at 2.8gm/dl, hematocrit
at 8.8%, white blood cells (WBCs) at 313.7 × 109 /L and platelets
at 166 × 109 /L. Subsequently, a bone marrow biopsy was performed, which was consistent with ALL. Immunophenotyping
by flow cytometry was performed and the gated population
showed reactivity with Pan-T-cell markers, i.e., CD7 and cCD3,
along with CD45, terminal deoxynucleotidyl transferase (TdT)
and CD34, with an aberrant expression of CD33. His conventional cytogenetic results were 46 XY chromosomes, while the
BCR-ABL transcript (p210/p190) was not detected. Tumor lysis
markers were within normal limits.
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The patient was diagnosed as T-ALL and was started on the
Medical Research Council (MRC) UKALL XII protocol. On day 17
of his induction protocol, the patient developed fever with dyspnea. Baseline lab results were sent and the abnormal findings
were the beta-d-glucan at >523.4 pg/mL (negative < 60 ng/mL)
and galactomannan at 8.06 (cutoff > 0.7). These findings, along
with bilateral infiltrates in the chest X-ray were consistent
with Aspergillus infection. The patient was intubated after
24 h due to worsening tachypnea and tachycardia. He was
started on voriconazole 200 mg twice a day. After 48 h, his
condition improved and he was shifted out of intensive care.
Though he did not receive chemotherapy on day 28 due to
complications, his bone marrow was in morphological remission and the minimal residual disease investigation showed
less than 0.01% T-lymphoblasts.
The patient remained in regular follow-up by a specialist in infectious diseases, along with the hematology team,
and re-started chemotherapy with induction phase 2. He then
received intensification with high-dose methotrexate and cranial irradiation, followed by consolidation.
While he was receiving consolidation block 4 chemotherapy, he developed febrile neutropenia and was prescribed
granulocyte-colony stimulating factor (G-CSF) 300 micrograms
(g) daily for 3 days at the hospital daycare unit. After receiving
three doses in hospital daycare, he presented to the emergency department with complaints of abdominal pain, fever
and cough for 3 days. On examination, he was febrile and
tachycardic. Due to the emerging pandemic of COVID-19, a
nasopharyngeal swab for SARS-Cov-2 by PCR was performed,
which was reported as detected. His CBC showed hemoglobin
at 10.2gm/dl, hematocrit at 27.4%, WBCs at <0.5 × 109 /L and
platelets at 5 × 109 /L. For febrile neutropenia, he was started
on broad-spectrum antibiotics and amphotericin and the
G-CSF dosage was increased to 300 g twice daily. His procalcitonin was at 0.97 ng/mL (cut off <0.5 ng/mL) and ferritin
was 22,078 ng/mL (the normal range being 22–322 ng/ml).
The blood chemistry was within normal limits, except for
the serum potassium, which was at 3.1 mmol/L. He received
platelet transfusions to maintain his platelet count above
10 × 109 /L.
After 48 h, the patient responded to this treatment. He
became afebrile, did not require mechanical ventilation and
his CBC parameters improved. On the fourth day of his admission, his counts were as follows: hemoglobin at 11.1gm/dl,
hematocrit at 31.5%, WBCs at 2.4 × 109 /L, absolute neutrophil
count at 1310 and platelets at 35 × 109 /L. His potassium
level was at 2.7 mmol/L and he continued to receive potassium replacement. He was discharged in stable condition and
advised to repeat the CBC and PCR for SARS-CoV-2
A week later, on repeat testing, the PCR for COVID-19 was
negative and the CBC showed hemoglobin at 10.9gm/dl, hematocrit at 31.5%, WBCs at 7.3 × 109 /L and platelets at 94 × 109 /L,
while the potassium level was at 3.5 mmol/L. He was afebrile
and stable. All family members and hospital staff who had
been exposed to this patient tested negative for COVID-19.
He received his next cycle of chemotherapy two months
later. However, a week after receiving vincristine, he presented with right-sided weakness and headache. Magnetic
Resonance Venography (MRV) and magnetic resonance imaging (MRI) showed extensive cerebral venous sinus thrombosis

and hemorrhagic venous infarct in left parietal lobe. The CBC
at that time showed hemoglobin at 9.6 gm/dl, hematocrit at
28.8%, WBCs at 4.2 × 109 /L, platelets at 65 × 109 /L and blasts at
59%. The investigations were consistent with disease relapse
(chronic neuroimmune disease (CND) and systemic). Thereafter, the patient opted for palliative care only.
A month later, he presented with complaints of sudden
onset shortness of breath after blood product transfusion
on the previous day, along with mild cough and hemoptysis. On arrival, he was in severe respiratory distress and his
oxygen saturation was at 77%. He was managed using noninvasive ventilation (NIV), but his condition deteriorated rapidly
and he developed bradycardia and later pulseless electrical
activity (PEA). Advanced directives by the patient were do-notresuscitate (DNR) and he expired thereafter.

Discussion
Few cases of concomitant occurrence of ALL with COVID-19
have been reported so far and the course of the infection has
been generally mild.5 However, even in the midst of a deadly
pandemic, ALL itself remains a huge threat to those that it
afflicts, even when they are in remission, as was seen in our
case.6
Zeidan et al. recently reported recommendations from
a panel of international experts about the management
of hematological malignancies in adults in the COVID-19
pandemic.7 It was suggested to consider delaying treatment
for ALL, given the risk of severe COVID-19 with chemotherapy.8
Antitumor treatment <14 days previously has been reported
as a risk factor for severe COVID-19. All patients should be
tested for SARS-CoV-2 before starting therapy and, in case of
a positive test, treatment should be delayed by 10–14 days,
except intrathecal therapies for central nervous system (CNS)
symptoms. Similar recommendations were put forward by the
French Society for the Fight against Cancers and Leukemias in
Children and Adolescents (SFCE).6
In the situation that a patient is positive for SARS-CoV-2,
but requires urgent initiation of induction treatment, it is recommended to treat while monitoring vigilantly for COVID-19
symptoms and disease course. If symptoms develop, therapy
should be discontinued and early initiation of cytokine modulators should be considered.9 For induction, it is recommended
to consider minimizing steroid exposure and reducing the
dose of daunorubicin and PEGylated asparaginase in older
patients and to delay using anti-CD20 monoclonal antibodies.7
Second-generation tyrosine kinase inhibitors with reduced
dose steroids should be used in the Philadelphia chromosomepositive disease.7,10
If patients are positive for minimal residual disease after
two cycles of chemotherapy, using blinatumomab is recommended, whereas if patients are negative for minimal residual
disease and have already received most of their treatment,
moving on to maintenance therapy is suggested. In the maintenance phase, reducing the dose of steroids and avoiding
vincristine is recommended and using blinatumomab for
minimal residual disease in the Philadelphia chromosomenegative B-cell ALL remains standard.7
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In addition, patients without COVID-19, should receive
abundant growth factor support to hasten the recovery of
the neutrophil count and to maintain an absolute neutrophil
count of more than 1000 cells per L across all phases of therapy. However, in moderate-to-severe COVID-19, the benefit of
growth factor support should be weighed against the potential risk of exacerbating the pulmonary complications related
to COVID-19.7 Use of G-CSF in our patient could be one of
the factors that resulted in a faster recovery. At the time of
the patient’s COVID-19 diagnosis, the pandemic was in its initial stages and guidelines on chemotherapy with concomitant
COVID-19 were evolving. However, with the passage of time
the guidelines have developed as mentioned above.6,7

Conclusion
We present a case of COVID-19 recovery in a patient with
underlying leukemia who presented with concomitant febrile
neutropenia (FN) and COVID-19. COVID-19 should be suspected in FN even in the absence of other symptoms and G-CSF
can be used in these patients for WBC recovery. In our case,
the patient was able to survive COVID-19, but, unfortunately,
had a relapse of ALL. Managing hematological malignancies
effectively while trying to minimize the risk of severe COVID19 due to immunosuppression secondary to chemotherapy is a
challenging clinical situation, with evolving guidelines aiding
clinical decision making.
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